Randomized Phase II Study of Irinotecan and Cetuximab with or Wit

This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery. Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or without vemurafenib in treating colorectal cancer.

September 25, 2015

  • Clinical Trial Information

    Trial Contact: Miles, Erin

    Trial Phone: 321.841.7607

  • Age Group: Adult

    Phase: Drug: Phase II

    Principal Investigator: Omar R. Kayaleh, MD

    Sub Investigators: N/A

    IRB No:

    Secondary Protocol No: SWOG 1406

    Applicable Disease Sites: Colorectal cancer